ERK KiMBI discriminates between brain-penetrantand nonpenetrant MEK inhibitors, reveals blood-tumor barrier leakinessin xenograft models, and reports MEK inhibitor pharmacodynamics innative brain tissues and intracranial xenografts. This evidence concerns the gene MAP2K7 and neoplasm.